Angry Birds Maker Posts Loss Despite Jump in Sales

Angry Birds Maker Posts Loss Despite Jump in Sales

Finland’s Rovio Entertainment, creator of the popular smartphone game Angry Birds, on Thursday posted a loss for the third quarter despite rising sales, as it increased its investments with a view to boost its winnings in future.

Sales reached EUR 70.7 million (nearly $84 million) in the third quarter compared to 50 million the previous year, but year-on-year the company lost EUR 800,000.

Rovio posted a profit of EUR 3.9 million in the third quarter of 2016.

The company said this quarter’s negative result was expected as it invested EUR 22 million in top performing games, hoping this would boost its profits in future.

“In line with our growth strategy, we significantly increased our investments in user acquisition, which predictably led to a decline in profitability,” Rovio chief executive Kati Levoranta said in a statement.

“We expect the payback time for these investments to be 8 to 10 months,” Levoranta said, adding the launch of the new Angry Birds Match game could become one of the company’s “best performing”.

The group entered the Helsinki Stock Exchange at the end of September and was valued at 950 million euros.

On Thursday morning, the company’s share price was down by 19 percent.

Rovio has accelerated its diversification in recent years.

The release of the Angry Birds movie (2016), produced by Sony Entertainment, was a huge success that grossed $350 million worldwide, and is expected to help bolster Rovio profits in 2017 and 2018.

The company also runs Angry Birds theme parks in several countries, including Finland, China and Spain.

It oversees the publication of children’s books in a dozen languages, while boasting an average of 80 million active players per month and 11 million per day.

[“Source-gadgets.ndtv”]

Biocon shares gain over 2% on launch of cancer drug KRABEVA in India

Biocon share price gained 2.5 percent intraday Thursday after the biopharmaceuticals firm has launched KRABEVA, a biosimilar Bevacizumab, in India.

The drug is used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India.

“We believe KRABEVA will be an important addition to oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India,” Arun Chandavarkar, CEO and joint MD, Biocon said.

KRABEVA is the second key oncologic biosimilar product from Biocon’s global biosimilars portfolio to be launched in India, in order to address the unmet patient need for affordable biological therapies.

The product is being offered to patients at an MRP of Rs 24,000 for 100 mg / 4 ml vials and Rs 39,990 for 400 mg / 16 ml vials.

KRABEVA is being launched post successful completion of phase III clinical trials and approval of company’s marketing authorisation application by the Drug Controller General of India.

At 11:02 hours IST, the stock price was quoting at Rs 418.50, up Rs 9.90, or 2.42 percent on the BSE.

source:-.moneycontrol.

Facebook Messenger Testing Snapchat-Like Streaks, Gets 4K Resolution Photo Support

Facebook Messenger Testing Snapchat-Like Streaks, Gets 4K Resolution Photo Support

HIGHLIGHTS

  • For streaks, Messenger shows a lightning bolt icon and days counter
  • Streaks provides a glance to ‘fun facts’ about the most active contacts
  • 4K resolution support is rolling out in limited regions

Taking on the competition, Facebook is testing a ‘Streaks’ feature in Messenger that is also used by Snapchat. The Menlo Park, California-headquartered company has also added 4K resolution support to its messaging service to uplift the visual experience. The latter feature is arriving for both Android and iOS platforms.

The first of the two updates to Facebook Messenger is the availability of Snapchat-like streaks feature that has been reported by certain users. The new feature would help Facebook to enhance engagements by letting users have a continuous conversation with their contacts. As spotted by Twitter user Case Sandberg, Facebook Messenger shows a lightning bolt icon next to the name of a person you have messaged for at least two days in a row. A counter is also available alongside the streak icon to reveal for how many days you both have been chatting on Messenger.

In a statement to Mashable, a Facebook spokesperson confirmed the presence of streaks. The spokesperson stated that the feature was in testing to let you “see at a glance fun facts” about the people you have spoken with on Messenger. It also adds that the feature will be visible if the person has been messaged at least “three days in a row”. Although the formal comment does not reveal an expansion of streaks, the feature could arrive on other Facebook-owned properties including Instagram and WhatsApp following its success on Messenger.

In addition to streaks, Facebook Messenger is receiving 4K support take the visual communication to new levels. The new support enables you to send and receive photos in up to 4096×4096 pixels resolution.

facebook 4k resolution support Facebook Messenger 4K  Facebook Messenger  Facebook

Facebook Messenger with 4K support

Despite supporting larger images, Messenger is touted to make it quicker to upload your favourite memories. Of course, you won’t have an as fast experience as the lighter version of Messenger offers on Android devices. But in the latest case, you have the ability to zoom into your memories to see the subjects and objects in detail.

You don’t need to select any specific settings to send 4K photos to your contacts. However, the latest version of the Messenger app is required to enable the new experience. Facebook has started rolling out the 4K resolution in the US, Canada, France, Australia, the UK, Singapore, Hong Kong, Japan, and South Korea. Other regions will receive the same update in the coming weeks.

As of September, Facebook Messenger has more than 1.3 billion monthly active users worldwide – on par with WhatsApp that reached the same milestone in July. The messaging service also offers a platform to third-party developers to host their apps and games in addition to features like bots, video calling, and peer-to-peer payments.

[“Source-gadgets.ndtv”]

Biocon climbs 2.65% on launch of cancer medicine

Shares of Biocon jumped as much as 2.65 per cent in Tuesday as the company has launched its cancer biosimilar drug KRABEVA in India.

Following a positive open at Rs 410 against the previous close of Rs 408.60, the scrip touched an intraday high of Rs 419.75 and a low of Rs 405.80. In terms of equity volume, 10.29 lakh shares traded on the BSE.

The stock ended the session up by 1.09 per cent at Rs 413.05.

According to a BSE filing, the biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India.

Biocon CEO and Joint MD Arun Chandavarkar said: “With KRABEVA, we intend to provide a high quality, world-class biosimilar Bevacizumab as an affordable therapy option for patients of various types of cancer.”

The company believes that the product will be an important addition to its oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India, he added.

Source:-thehindubusinessline